Ocugen, Inc/$OCGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ocugen, Inc
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Ticker
$OCGN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
95
ISIN
US67577C1053
Website
Ocugen, Inc Metrics
BasicAdvanced
$330M
-
-$0.21
4.24
-
Price and volume
Market cap
$330M
Beta
4.24
52-week high
$1.98
52-week low
$0.52
Average daily volume
7.4M
Financial strength
Current ratio
2.604
Quick ratio
2.239
Long term debt to equity
195.344
Total debt to equity
199.969
Interest coverage (TTM)
-62.41%
Profitability
EBITDA (TTM)
-54.344
Gross margin (TTM)
-476.87%
Net profit margin (TTM)
-1,271.12%
Operating margin (TTM)
-1,261.43%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-61.33%
Return on equity (TTM)
-248.97%
Valuation
Price to revenue (TTM)
69.891
Price to book
20.73
Price to tangible book (TTM)
20.73
Price to free cash flow (TTM)
-6.083
Free cash flow yield (TTM)
-16.44%
Free cash flow per share (TTM)
-18.58%
Growth
Revenue change (TTM)
-31.56%
Earnings per share change (TTM)
-10.42%
3-year earnings per share growth (CAGR)
-16.20%
What the Analysts think about Ocugen, Inc
Analyst ratings (Buy, Hold, Sell) for Ocugen, Inc stock.
Bulls say / Bears say
Ocugen's OCU400 Phase 3 clinical trial for retinitis pigmentosa is progressing well, with potential BLA/MAA filings by mid-2026, indicating significant advancement in their gene therapy pipeline. (Ocugen Press Release)
The company secured $30 million in debt financing in November 2024, bolstering its financial position to support ongoing research and development activities. (Ocugen Press Release)
Ocugen's OCU410ST received Rare Pediatric Disease Designation from the FDA for the treatment of Stargardt disease, potentially expediting its development and approval process. (Ocugen Press Release)
Ocugen reported a net loss of $0.05 per share for the first quarter of 2025, reflecting ongoing financial challenges. (Ocugen Press Release)
The company's revenue for 2024 was $4.05 million, a decrease of 32.82% compared to the previous year, indicating declining sales. (Stock Analysis)
Ocugen has a high short interest of 22.32% of outstanding shares, suggesting that a significant number of investors are betting against the stock. (Stock Analysis)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Ocugen, Inc Financial Performance
Revenues and expenses
Ocugen, Inc Earnings Performance
Company profitability
Ocugen, Inc News
AllArticlesVideos
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
GlobeNewsWire·3 weeks ago
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
GlobeNewsWire·4 weeks ago
Ocugen To Present at BIO International Convention 2025
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ocugen, Inc stock?
Ocugen, Inc (OCGN) has a market cap of $330M as of July 11, 2025.
What is the P/E ratio for Ocugen, Inc stock?
The price to earnings (P/E) ratio for Ocugen, Inc (OCGN) stock is 0 as of July 11, 2025.
Does Ocugen, Inc stock pay dividends?
No, Ocugen, Inc (OCGN) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Ocugen, Inc dividend payment date?
Ocugen, Inc (OCGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Ocugen, Inc?
Ocugen, Inc (OCGN) has a beta rating of 4.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.